Xcytrin motexafin gadolinium: Phase II started

PCYC started an open-label, U.S. and Canadian Phase II trial in 45 patients. Patients will receive 10 daily doses of 5 mg/kg Xcytrin with whole brain radiation therapy (WBRT) followed by stereotactic ...